Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study
<p>Abstract</p> <p>Background</p> <p>Replicative phenotypic HIV resistance testing (rPRT) uses recombinant infectious virus to measure viral replication in the presence of antiretroviral drugs. Due to its high sensitivity of detection of viral minorities and its dissect...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-01-01
|
| Series: | Journal of Translational Medicine |
| Online Access: | http://www.translational-medicine.com/content/9/1/14 |
| _version_ | 1818961526243983360 |
|---|---|
| author | Martinetti Gladys Vernazza Pietro Hirschel Bernard Fux Christoph A Cavassini Matthias Bürgisser Philippe Yerly Sabine Böni Jürg von Wyl Viktor Hirsch Hans H Hamy François Louvel Séverine Glass Tracy R Fehr Jan Bernasconi Enos Günthard Huldrych F Battegay Manuel Bucher Heiner C Klimkait Thomas |
| author_facet | Martinetti Gladys Vernazza Pietro Hirschel Bernard Fux Christoph A Cavassini Matthias Bürgisser Philippe Yerly Sabine Böni Jürg von Wyl Viktor Hirsch Hans H Hamy François Louvel Séverine Glass Tracy R Fehr Jan Bernasconi Enos Günthard Huldrych F Battegay Manuel Bucher Heiner C Klimkait Thomas |
| author_sort | Martinetti Gladys |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Replicative phenotypic HIV resistance testing (rPRT) uses recombinant infectious virus to measure viral replication in the presence of antiretroviral drugs. Due to its high sensitivity of detection of viral minorities and its dissecting power for complex viral resistance patterns and mixed virus populations rPRT might help to improve HIV resistance diagnostics, particularly for patients with multiple drug failures. The aim was to investigate whether the addition of rPRT to genotypic resistance testing (GRT) compared to GRT alone is beneficial for obtaining a virological response in heavily pre-treated HIV-infected patients.</p> <p>Methods</p> <p>Patients with resistance tests between 2002 and 2006 were followed within the Swiss HIV Cohort Study (SHCS). We assessed patients' virological success after their antiretroviral therapy was switched following resistance testing. Multilevel logistic regression models with SHCS centre as a random effect were used to investigate the association between the type of resistance test and virological response (HIV-1 RNA <50 copies/mL or ≥1.5log reduction).</p> <p>Results</p> <p>Of 1158 individuals with resistance tests 221 with GRT+rPRT and 937 with GRT were eligible for analysis. Overall virological response rates were 85.1% for GRT+rPRT and 81.4% for GRT. In the subgroup of patients with >2 previous failures, the odds ratio (OR) for virological response of GRT+rPRT compared to GRT was 1.45 (95% CI 1.00-2.09). Multivariate analyses indicate a significant improvement with GRT+rPRT compared to GRT alone (OR 1.68, 95% CI 1.31-2.15).</p> <p>Conclusions</p> <p>In heavily pre-treated patients rPRT-based resistance information adds benefit, contributing to a higher rate of treatment success.</p> |
| first_indexed | 2024-12-20T12:14:50Z |
| format | Article |
| id | doaj.art-498dbebec85b4a659f85ff02f65ef092 |
| institution | Directory Open Access Journal |
| issn | 1479-5876 |
| language | English |
| last_indexed | 2024-12-20T12:14:50Z |
| publishDate | 2011-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj.art-498dbebec85b4a659f85ff02f65ef0922022-12-21T19:41:09ZengBMCJournal of Translational Medicine1479-58762011-01-01911410.1186/1479-5876-9-14Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort StudyMartinetti GladysVernazza PietroHirschel BernardFux Christoph ACavassini MatthiasBürgisser PhilippeYerly SabineBöni Jürgvon Wyl ViktorHirsch Hans HHamy FrançoisLouvel SéverineGlass Tracy RFehr JanBernasconi EnosGünthard Huldrych FBattegay ManuelBucher Heiner CKlimkait Thomas<p>Abstract</p> <p>Background</p> <p>Replicative phenotypic HIV resistance testing (rPRT) uses recombinant infectious virus to measure viral replication in the presence of antiretroviral drugs. Due to its high sensitivity of detection of viral minorities and its dissecting power for complex viral resistance patterns and mixed virus populations rPRT might help to improve HIV resistance diagnostics, particularly for patients with multiple drug failures. The aim was to investigate whether the addition of rPRT to genotypic resistance testing (GRT) compared to GRT alone is beneficial for obtaining a virological response in heavily pre-treated HIV-infected patients.</p> <p>Methods</p> <p>Patients with resistance tests between 2002 and 2006 were followed within the Swiss HIV Cohort Study (SHCS). We assessed patients' virological success after their antiretroviral therapy was switched following resistance testing. Multilevel logistic regression models with SHCS centre as a random effect were used to investigate the association between the type of resistance test and virological response (HIV-1 RNA <50 copies/mL or ≥1.5log reduction).</p> <p>Results</p> <p>Of 1158 individuals with resistance tests 221 with GRT+rPRT and 937 with GRT were eligible for analysis. Overall virological response rates were 85.1% for GRT+rPRT and 81.4% for GRT. In the subgroup of patients with >2 previous failures, the odds ratio (OR) for virological response of GRT+rPRT compared to GRT was 1.45 (95% CI 1.00-2.09). Multivariate analyses indicate a significant improvement with GRT+rPRT compared to GRT alone (OR 1.68, 95% CI 1.31-2.15).</p> <p>Conclusions</p> <p>In heavily pre-treated patients rPRT-based resistance information adds benefit, contributing to a higher rate of treatment success.</p>http://www.translational-medicine.com/content/9/1/14 |
| spellingShingle | Martinetti Gladys Vernazza Pietro Hirschel Bernard Fux Christoph A Cavassini Matthias Bürgisser Philippe Yerly Sabine Böni Jürg von Wyl Viktor Hirsch Hans H Hamy François Louvel Séverine Glass Tracy R Fehr Jan Bernasconi Enos Günthard Huldrych F Battegay Manuel Bucher Heiner C Klimkait Thomas Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study Journal of Translational Medicine |
| title | Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study |
| title_full | Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study |
| title_fullStr | Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study |
| title_full_unstemmed | Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study |
| title_short | Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study |
| title_sort | replicative phenotyping adds value to genotypic resistance testing in heavily pre treated hiv infected individuals the swiss hiv cohort study |
| url | http://www.translational-medicine.com/content/9/1/14 |
| work_keys_str_mv | AT martinettigladys replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT vernazzapietro replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT hirschelbernard replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT fuxchristopha replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT cavassinimatthias replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT burgisserphilippe replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT yerlysabine replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT bonijurg replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT vonwylviktor replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT hirschhansh replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT hamyfrancois replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT louvelseverine replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT glasstracyr replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT fehrjan replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT bernasconienos replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT gunthardhuldrychf replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT battegaymanuel replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT bucherheinerc replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy AT klimkaitthomas replicativephenotypingaddsvaluetogenotypicresistancetestinginheavilypretreatedhivinfectedindividualstheswisshivcohortstudy |